Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TREHALOSE DIHYDRATE CRS (250 MG)

TREHALOSE DIHYDRATE CRS (250 MG)

6138-23-4

DISCOVER
FILGRASTIM CRS (0.3 ML)

FILGRASTIM CRS (0.3 ML)

ND

DISCOVER
CEFRADINE IMPURITY MIXTURE CRS (0.04 MG)

CEFRADINE IMPURITY MIXTURE CRS (0.04 MG)

NA

DISCOVER
ARISTOLOCHIC ACID FOR SYSTEM SUITABILITY CRS (1 MG)

ARISTOLOCHIC ACID FOR SYSTEM SUITABILITY CRS (1 MG)

10190-99-5

DISCOVER
DEXAMETHASONE FOR SYSTEM SUITABILITY CRS (15 MG)

DEXAMETHASONE FOR SYSTEM SUITABILITY CRS (15 MG)

50-02-2

DISCOVER
TIOTROPIUM IMPURITY MIXTURE CRS (0.08 MG)

TIOTROPIUM IMPURITY MIXTURE CRS (0.08 MG)

NA

DISCOVER
ORPHENADRINE FOR PEAK IDENTIFICATION CRS (0.44 MG)

ORPHENADRINE FOR PEAK IDENTIFICATION CRS (0.44 MG)

341-69-5

DISCOVER
CAPTOPRIL FOR SYSTEM SUITABILITY CRS (20 MG)

CAPTOPRIL FOR SYSTEM SUITABILITY CRS (20 MG)

62571-86-2

DISCOVER
TROLAMINE IMPURITY B CRS (1.5ML)

TROLAMINE IMPURITY B CRS (1.5ML)

111-42-2

DISCOVER
TROLAMINE IMPURITY A CRS (250MG)

TROLAMINE IMPURITY A CRS (250MG)

141-43-5

DISCOVER
ARISTOLOCHIC ACID  I CRS (11 MG)

ARISTOLOCHIC ACID I CRS (11 MG)

313-67-7

DISCOVER
SALBUTAMOL IMPURITY J CRS (0.45 µG)

SALBUTAMOL IMPURITY J CRS (0.45 µG)

NA

DISCOVER